Is Pfizer Stock a Buy Now?
Last year, pharmaceutical giant Pfizer (NYSE: PFE) reported the highest revenue it had ever had in a single calendar year. But in 2023, the drugmaker has substantially underperformed the market, and its shares are down by 41% year to date. These two facts aren't unrelated. Pfizer generated record-breaking sales in 2021 and 2022 thanks to its coronavirus portfolio, which has lost momentum since the COVID-19 pandemic has largely receded.
Even so, investors could be underestimating Pfizer's potential. Let's find out why the healthcare giant is still worth investing in, especially at current levels.
Source Fool.com
Pfizer Inc. Stock
€25.63
-2.550%
The stock is one of the favorites of our community with 31 Buy predictions and 4 Sell predictions.
As a result the target price of 41 € shows a very positive potential of 60.0% compared to the current price of 25.63 € for Pfizer Inc..
